Drugs and FDA
Sanofi Pompe drug shortage continues to disrupt patient infusions
Sanofi said shipping delays could interrupt infusions for some U.S. patients through the end of November.

Sanofi’s shortage of its Pompe disease treatments is continuing to disrupt infusions, with some patients facing canceled doses. The company said it has restored supply in some countries, but shipping delays could interrupt infusions for some U.S. patients through the end of November. Patients typically receive Lumizyme or Nexviazyme every two weeks.
Sanofi said issues at its manufacturing facility in Ireland, including work to address ongoing FDA concerns, contributed to the supply disruption. The FDA inspected the plant between January 12 and January 20, 2026, and found violations involving two unrelated drugs. On June 22, the agency sent Sanofi a warning letter saying it had not addressed the “underlying failure” to comply with manufacturing requirements. Sanofi said there were no issues with drug quality and advised patients to consult a health professional before switching treatments, which it said are not interchangeable.


